NCT06917573 (PALACE) is a Phase 2 clinical trial of Cemiplimab in Non Small Cell Lung Cancer Metastatic, sponsored by Fundación GECP.

Who is sponsoring NCT06917573?

NCT06917573 is sponsored by Fundación GECP.

What drugs are being tested in NCT06917573?

Interventions in NCT06917573: Cemiplimab, Carboplatin, Paclitaxel.

What condition does NCT06917573 study?

NCT06917573 studies Non Small Cell Lung Cancer Metastatic, Lung Diseases, Stage IV Non-small Cell Lung Cancer, Stage III Non-small Cell Lung Cancer, Respiratory Tract Neoplasms, Thoracic Neoplasms.

Is NCT06917573 still recruiting?

NCT06917573 is currently recruiting now. Last updated 19 November 2025.

Last reviewed 2025-11-19 · How we verify

NCT06917573: PALACE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PALACE: Cemiplimab Trial According to ctDNA Levels

Recruiting now Phase 2 Last updated 19 November 2025

What this trial tests

Phase 2 trial testing Cemiplimab in Non Small Cell Lung Cancer Metastatic in 63 participants. Currently enrolling.

Timeline

29 July 2025

Primary endpoint
30 December 2031

30 December 2031

Quick facts

Lead sponsor	Fundación GECP
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	63
Start date	29 July 2025
Primary completion	30 December 2031
Estimated completion	30 December 2031
Sites	20 locations across Spain

Drugs / interventions tested

Cemiplimab (CEMIPLIMAB) — full drug profile →
Carboplatin (Carboplatin) — full drug profile →
Paclitaxel — full drug profile →

Conditions studied

Non Small Cell Lung Cancer Metastatic — all drugs for Non Small Cell Lung Cancer Metastatic →
Lung Diseases — all drugs for Lung Diseases →
Stage IV Non-small Cell Lung Cancer — all drugs for Stage IV Non-small Cell Lung Cancer →
Stage III Non-small Cell Lung Cancer — all drugs for Stage III Non-small Cell Lung Cancer →

Sponsor

Fundación GECP — full company profile →

Who can join

18 and older, any sex, with Non Small Cell Lung Cancer Metastatic or Lung Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, non-randomised, phase II, multicenter clinical trial. 63 stage IV or stage IIIB/C not candidates for definitive chemo/radiotherapy or surgical resection non-small cell lung cancer (NSCLC) per the 8th edition TNM with no prior systemic anti-cancer therapy will be enrolled in this trial to determine whether therapy decision making based on ctDNA analysis improves overall survival.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Cemiplimab

Trials testing the same drug.

NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
NCT07179315 — A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Tr · Phase 2 · not yet recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
NCT07195734 — Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer · Phase 2 · recruiting

Other recruiting trials for Non Small Cell Lung Cancer Metastatic

Currently open trials in the same condition.

NCT07190677 — First-line Therapy With Nivolumab Plus Ipilimumab in Combination With Chemotherapy for Metatastatic NSCLC (NICReWo Trial · recruiting
NCT06473961 — A Phase Ib Study of GC101 in NSCLC · Phase 1 · recruiting
NCT05864794 — Value of Screening MRI Brain in Stage IV Non-small Cell Lung Cancer · NA · recruiting
NCT05853887 — Liquid Biopsy Based NGS in Newly Diagnosed NSCLC · NA · active not recruiting
NCT05657873 — A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) · Phase 2 · recruiting

Other Fundación GECP trials

Trials by the same sponsor.

NCT07247786 — Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI · Phase 2 · not yet recruiting
NCT07242547 — Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients · Phase 2 · recruiting
NCT07153445 — Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lu · Phase 2 · recruiting
NCT06431633 — Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously · Phase 3 · recruiting
NCT06634199 — Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06917573 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundación GECP
Last refreshed: 19 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06917573.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing